| Acquired by | Sanofi Aventis |
| Price | $4B |
| Date | 7/09 |
| Website | merial.com |
| Category | BioTech |
| Phone | 678-638-3000 |
| Employees | |
| Founded | 1997 |
| Description | livestock pharmaceuticals and vaccines |
Merial Limited, an animal healthcare company, engages in the research, development, and production of pharmaceutical products and vaccines for livestock, pets, and wildlife.
It offers products in the fields of anaesthetic, antiparasitic, antimicrobial, gastrointestinal, respiratory, and cardiovascular medicines, as well as vaccines to treat diseases, such as Newcastle Disease, Marek’s Disease, and Avian Flu in birds. The company’s products include IVOMEC for the treatment of parasites in cattle, sheep, and swine; and FRONTLINE for the treatment of dogs and cats. It serves veterinarians, pet owners, farmers, and food animal producers internationally.
The company was founded in 1997 through a 50-50 joint venture of the animal health assets of Rhône-Poulenc and Merck & Co, and it is headquartered in Duluth, Georgia. It operates in Argentina, the Netherlands, Australia, New Zealand, Brazil, Philippines, Chile, Russia, China, Singapore, France, Spain, Germany, Taiwan, Italy, Thailand, Japan, the United Kingdom, Korea, the United States, Latinoamerica, Uruguay, Mexico, and internationally.
Merial Limited operates as a subsidiary of Sanofi-Aventis, which acquired Rhône-Poulenc and on September 17, 2009 acquired Merck’s 50% stake.
